1:08 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Clinical News

Blueprint reports early data for RET inhibitor

Blueprint Medicines Corp. (NASDAQ:BPMC) reported data from the Phase I ARROW trial of BLU-667 to treat ret proto-oncogene (RET)-altered solid tumors. BLU-667 is a RET inhibitor.

Among 14 evaluable patients with RET-altered non-small cell lung cancer (NSCLC), once-daily BLU-667 led to an overall response rate (ORR) of 50%, including five confirmed partial responses (PRs) and two unconfirmed PRs.

Among 25 patients with RET-altered medullary thyroid cancer (MTC), BLU-667 led to an ORR of 40%. One patient had a complete response and nine had PRs, including five confirmed PRs. Another patient with RET-altered papillary thyroid cancer (PTC) had an unconfirmed PR.

BLU-667 also led to radiographic tumor reductions in 85% of NSCLC patients and 83% of MTC patients. BLU-667 was well tolerated with seven patients reporting dose-limiting toxicities (DLTs) at doses of up to 600 mg once daily. The maximum tolerated dose (MTD) was once-daily 400 mg BLU-667.

Data were presented at the American Association for Cancer Research meeting in Chicago.

In the trial's expansion portion, Blueprint will evaluate once-daily 400 mg BLU-667 in patients with RET-altered NSCLC, including some previously treated with a tyrosine kinase inhibitor, MTC and other RET-altered solid tumors.

Blueprint slipped $12.52 (13%) to $86.46 on Monday. Despite the losses, Blueprint's share price has still doubled since August, and remains more than two and a half times its 52-week low of $34.38 in late May 2017.

Loxo Oncology Inc. (NASDAQ:LOXO), which is developing rival RET inhibitor LOXO-292, gained $10.46 to $133.45 on Monday. Loxo plans to present data from a Phase I trial of LOXO-292 to treat RET-altered cancers, including NSCLC and MTC, at the American Society of Clinical Oncology meeting in Chicago in June.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD